OxyContin®LP 40mg (Mundipharma) 🇬🇧

Indicated for the management of moderate to severe pain requiring continuous, around-the-clock opioid treatment, such as chronic cancer pain or non-malignant chronic pain

**Addiction Risk: High potential for abuse and addiction; use in opioid-naïve patients can lead to fatal respiratory depression

**Concomitant Use with CNS Depressants: Combining with benzodiazepines or alcohol increases the risk of respiratory depression

**Use in Elderly or Hepatic/Renal Impairment: Dose adjustments and close monitoring are necessary

**Developed by: Purdue Pharma L.P.

**Year Introduced: 1996

**Notable Feature: First extended-release oxycodone formulation providing 12-hour pain relief

**Misuse Methods: Reports of crushing, chewing, or injecting to achieve rapid onset, leading to increased addiction and overdose risks

**Societal Impact: Widespread misuse contributed to the opioid epidemic in the U.S., resulting in legal actions against Purdue Pharma for misleading marketing practices

**Reformulation: In 2010, the formulation was modified to include abuse-deterrent properties to prevent crushing and misuse

**Regulatory Status: Classified as a Schedule II controlled substance in the U.S., indicating high potential for abuse and strict regulatory controls